Lidocaine hydrochloride is under clinical development by Scilex Holding and currently in Phase II for Neck Pain (Cervicalgia). According to GlobalData, Phase II drugs for Neck Pain (Cervicalgia) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Lidocaine hydrochloride LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lidocaine hydrochloride overview
Lidocaine hydrochloride (ZTlido) is an amide type local anesthetic agent. It is formulated as patch for topical application. ZTlido is indicated for the relief of pain associated with post-herpetic neuralgia (PHN), also referred to as post-shingles pain, chronic neck pain and low back pain.
The drug candidate is applied through transdermal route as a patch. The drug candidate is a next-generation branded lidocaine transdermal patch (1.8%). The drug candidate is a lidocaine transdermal patch (5.4%) for low back pain (SP-103).The drug candidate is developed based on Scilex proprietary patch technology that utilizes a proprietary single-layer anhydrous, drug-in-adhesive, topical delivery system to keep its patches thin and targets local drug delivery. It was under development for the treatment of post-herpetic neuralgia in EU.
Scilex Holding overview
Scilex Holding (Scilex), a subsidiary of Sorrento Therapeutics Inc, is a pharmaceutical manufacturing company. The company specializes in development and commercialization of non-opioid therapeutic pain management products for the treatment of gout in adults and oral solution for the acute treatment of migraine in adults. Its drug product portfolio includes ZTLido, Gloperba, and Elyxyb. The company service offerings include preclinical research, clinical trials, research and development, drug development, and drug discovery programs. Scilex is headquartered in Palo Alto, California, the US.
For a complete picture of Lidocaine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
